On November 5, IDEXX Laboratories fell 3.03% in Regular Trading, trading at $677.025 per share, with turnover of $105 million.
The main backdrop remains the company’s recently reported third-quarter results, which exceeded market expectations, alongside higher full-year guidance, even as the shares retreated during the session.
IDEXX Laboratories previously reported third-quarter EPS of $4.01 and comparable EPS of $3.96, both above consensus estimates of $3.71 and $3.73, respectively. Revenue was $1.214 billion, ahead of the expected $1.191 billion. The company also raised its full-year comparable EPS growth outlook to 15% to 16% from 13% to 15%, and lifted revenue guidance to $4.74 billion-$4.77 billion from $4.70 billion-$4.75 billion. Recent analyst commentary highlighted resilient pricing despite softer veterinary visit trends, while some brokerages also adjusted target prices after the report.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments